BioWorld

Dec. 20, 2002

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today) Read More

ICOS Drops Pafase After Interim Analysis Of Phase III Sepsis Trial

Luciferase Probe Sees Real-Time Imaging Of Apoptosis In Drug's Performance - Noninvasively

Genentech, Tanox, Novartis Finalize Application For Xolair

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...